Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program

An In-Depth Look at How Good Clinical Practices Ensure Ethical Conduct
of High Quality Research and the Safety of Study Subjects

LAUSANNE, Switzerland--(BUSINESS WIRE)--Dec. 12, 2017--
Philip Morris International Inc. (PMI)
(NYSE/Euronext Paris: PM) today released its latest Scientific Update
for Smoke-Free Products, a regular publication on its research efforts
to develop and assess a range of smoke-free alternatives to cigarettes.
The latest issue of the Scientific
Update can be found at this
link.

Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire)

This issue of theScientific Update provides a closer look at
some of the principles and practices on which PMI’s scientific
assessment program is built. Director Medical Affairs Dr. Patrick
Picavet describes specific examples from PMI’s clinical program that
highlight the company’s commitment to the implementation of best
practices, transparent research and the well-being of clinical trial
participants.

Picavet stated, “The performance of clinical studies is a complicated
process. Strict implementation of Good Clinical Practices is
particularly important to assure the quality and consistency of the
research and to address unexpected events that can occur during a study.
These Practices are key to the validity of data and the safety of study
participants.”

Beyond recent events and publications, this issue also describes PMI’s
progress towards sharing all raw data from studies on IQOS in
part through the new data-sharing platform called INTERVALS.

Prof. Manuel Peitsch, PMI’s Chief Scientific Officer, elaborates: “PMI
is committed to openly sharing the research behind our smoke-free
products. That’s why we are using our latest Scientific Update to
explain the rigor behind our clinical program. We are going further by
gradually making the data and results from the non-clinical and clinical
program around our leading smoke-free product, IQOS, available to the
public by early 2018.”

PMI’s extensive research and assessment program is inspired by the
well-recognized practices of the pharmaceutical industry and in line
with the draft guidance of the U.S. FDA for Modified Risk Tobacco
Product (MRTP) Applications. PMI employs over 400 world-class
scientists, engineers and experts who conduct rigorous research,
including laboratory and clinical studies, as well as ground-breaking
systems toxicology. The assessment program also includes studies on
actual product use and correct understanding of product communications,
as well as post-market research.

About Philip Morris International Inc. (“PMI”)

Philip Morris International Inc. (PMI) is a leading international
tobacco company, with six of the world's top 15 international brands and
products sold in more than 180 markets. In addition to the manufacture
and sale of cigarettes, including Marlboro, the number one
global cigarette brand, and other tobacco products, PMI is engaged in
the development and commercialization of reduced-risk products (RRPs).
RRPs is the term PMI uses to refer to products that present, are likely
to present, or have the potential to present less risk of harm to
smokers who switch to these products versus continued smoking. Through
multidisciplinary capabilities in product development, state-of-the-art
facilities, and industry-leading scientific substantiation, PMI aims to
provide an RRP portfolio that meets a broad spectrum of adult smoker
preferences and rigorous regulatory requirements. For more information,
see our PMI and PMI
Science websites.

* Please note that the company may file several documents with the SEC on the same day, which will result in multiple email alerts (one for each filing). Signing up for the end-of-day option will eliminate the multiple email issue, but it will also affect the timeliness of the notification with respect to the filing time.

Thank you for subscribing! Your email address has been added to our list.